A methylated oligonucleotide inhibits IGF2 expression and enhances survival in a model of hepatocellular carcinoma

Journal of Clinical Investigation

Volumn 111, Issue 2, 2003, Pages 265-273

  Yao, Xiaoming ^a   Hu, Ji Fan ^b   Daniels, Mark ^a   Shiran, Hadas ^b   Zhou, Xiangjun ^b   Yan, Huifan ^c   Lu, Hongqi ^c   Zeng, Zhilan ^a   Wang, Qingxue ^a   Li, Tao ^a   Hoffman, Andrew R ^a,d  

^a STANFORD UNIVERSITY   (United States)

^b GMR Epigenetics Corporation   (United States)

^c Shanghai Inst Pharmaceutical I   (China)

^d VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSINE; GUANINE; MESSENGER RNA; MITOGENIC AGENT; OLIGONUCLEOTIDE; SOMATOMEDIN B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; GENE EXPRESSION; GENE INDUCTION; GENE LOCUS; GENE SILENCING; HUMAN; HUMAN CELL; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; RNA SEQUENCE; TUMOR GROWTH;

BASE SEQUENCE; DNA METHYLATION; GENE EXPRESSION REGULATION; HUMANS; INSULIN-LIKE GROWTH FACTOR II; LIVER NEOPLASMS; MOLECULAR SEQUENCE DATA; OLIGONUCLEOTIDES; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 0037243999     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200315109     Document Type: Article

References (56)

1. Nakae, J., Kido, Y., and Accili, D. 2001. Distinct and overlapping functions of insulin and IGF-I receptors. Endocr. Rev. 22:818-835.
2. Cariani, E., et al. 1988. Differential expression of insulin-like growth factor II mRNA in human primary liver cancers, benign liver tumors, and liver cirrhosis. Cancer Res. 48:6844-6849.
3. Kim, S.O., Park, J.G., and Lee, Y.I. 1996. Increased expression of the insulin-like growth factor I (IGF-I) receptor gene in hepatocellular carcinoma cell lines: implications of IGF-I receptor gene activation by hepatitis B virus X gene product. Cancer Res. 56:3831-3836.
4. Pulford, D.J., Falls, J.G., Killian, J.K., and Jirtle, R.L. 1999. Polymorphisms, genomic imprinting and cancer susceptibility. Mutat. Res. 436:59-67.
5. Zhang, L., et al. 1997. Gene expression profiles in normal and cancer cells. Science. 276:1268-1272.
6. Schirmacher, P., et al. 1992. Reactivation of insulin-like growth factor II during hepatocarcinogenesis in transgenic mice suggests a role in malignant growth. Cancer Res. 52:2549-2556.
7. Hu, J.F., et al. 1997. Repression of hepatitis B virus (HBV) transgene and HBV-induced liver injury by low protein diet. Oncogene. 15:2795-2801.
8. Su, Q., et al. 1994. Expression of insulin-like growth factor II in hepatitis B, cirrhosis and hepatocellular carcinoma: its relationship with hepatitis B virus antigen expression. Hepatology. 20:788-799.
9. Rogler, C.E., et al. 1994. Altered body composition and increased frequency of diverse malignancies in insulin-like growth factor-II transgenic mice. J. Biol. Chem. 269:13779-13784.
10. Christofori, G., Naik, P., and Hanahan, D. 1994. A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis. Nature. 369:414-418.
11. Haddad, R., and Held, W.A. 1997. Genomic imprinting and IGF-2 influence liver tumorigenesis and loss of heterozygosity in SV40 T antigen transgenic mice. Cancer Res. 57:4615-4623.
12. Christofori, G., Naik, P., and Hanahan, D. 1995. Deregulation of both imprinted and expressed alleles of the insulin-like growth factor 2 gene during beta-cell tumorigenesis. Nat. Genet. 10:196-201.
13. Gonzalgo, M.L., and Jones, P.A. 1997. Mutagenic and epigenetic effects of DNA methylation. Mutat. Res. 386:107-118.
14. Cameron, E.E., Bachman, K.E., Myohanen, S., Herman, J.G., and Baylin, S.B. 1999. Synergy of demethylation and histone deacetylase inhibition in the re- expression of genes silenced in cancer. Nat. Genet. 21:103-107.
15. Hu, J.F., Vu, T.H., and Hoffman, A.R. 1996. Promoter-specific modulation of insulin-like growth factor II genomic imprinting by inhibitors of DNA methylation. J. Biol. Chem. 271:18253-18262.
16. Toulme, J.J., Di Primo, C., and Moreau, S. 2001. Modulation of RNA function by oligonucleotides recognizing RNA structure. Prog. Nucleic Acid Res. Mol. Biol. 69:1-46.
17. Szyf, M., and Detich, N. 2001. Regulation of the DNA methylation machinery and its role in cellular transformation. Prog Nucleic Acid Res. Mol. Biol. 69:47-79.
18. Jones, P.L., et al. 1998. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat. Genet. 19:187-191.
19. Hu, J.F., Oruganri, H., Vu, T.H., and Hoffman, A.R. 1998. The role of histone acetylation in the allelic expression of the imprinted human insulin-like growth factor II gene. Biochem. Biophys. Res. Commun. 251:403-408.
20. Hu, J., Vu, T., and Hoffman, A. 1995. Differential biallelic activation of three insulin-like growth factor II promoters in the mouse central nervous system. Mol. Endocrinol. 9:628-636.
21. Li, T., et al. 2002. An imprinted PEG1/MEST antisense expressed pre-dominantly in human testis and in mature spermatozoa. J. Biol. Chem. 277:13518-13527.
22. Hu, J.F., Oruganti, H., Vu, T.H., and Hoffman, A.R. 1998. Tissue-specific imprinting of the mouse insulin-like growth factor II receptor gene correlates with differential allele-specific DNA methylation. Mol. Endocrinol. 12:220-232.
23. Frommer, M., et al. 1992. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc. Natl. Acad. Sci. USA. 89:1827-1831.
24. Hu, J.F., Nguyen, P.H., Pham, N.V., Vu, T.H., and Hoffman, A.R. 1997. Modulation of IGF-2 genomic imprinting in mice induced by 5-azacytidine, an inhibitor of DNA methylation. Biol. Endocrinol. 11:1891-1898.
25. Vu, T.H., et al. 2000. Symmetric and asymmetric DNA methylation in the human IGF-2-H19 imprinted region. Genomics. 64:132-143.
26. Lubbert, M., Brugger, W., Mertelsmann, R., and Kanz, L. 1996. Developmental regulation of myeloid gene expression and demethylation during ex vivo culture of peripheral blood progenitor cells. Blood. 87:447-455.
27. Stoger, R., et al. 1993. Maternal-specific methylation of the imprinted mouse IGF-2r locus identifies the expressed locus as carrying the imprinting signal. Cell. 73:61-71.
28. Hark, A. T., et al. 2000. CTCF mediates methylation-sensitive enhancer-blocking activity at the H19/IGF-2 locus. Nature. 405:486-489.
29. Bell, A.C., and Felsenfeld, G. 2000. Methylation of a CTCF-dependent boundary controls imprinted expression of the IGF-2 gene. Nature. 405:482-485.
30. Nakagawa, H., et al. 2001. Loss of imprinting of the insulin-like growth factor II gene occurs by biallelic methylation in a core region of H19-associated CTCF-binding sites in colorectal cancer. Proc. Natl. Acad. Sci. USA 98:591-596.
31. Panning, B., and Jaenisch, R. 1996. DNA hypomethylation can activate Xist expression and silence X-linked genes. Genes Dev. 10: 1991-2002.
32. Beard, C., Li, E., and Jaenisch, R. 1995. Loss of methylation activates Xist in somatic but not in embryonic cells. Genes Dev. 9:2325-2334.
33. Schweizer, J., Valenza-Schaerly, P., Goret, F., and Pourcel, C. 1998. Control of expression and methylation of a hepatitis B virus transgene by strain-specific modifiers. DNA Cell Biol. 17:427-435.
34. Siegfried, Z, et al., 1999. DNA methylation represses transcription in vivo. Nat. Genet. 22:203-206.
35. Scrable, H., and Stambrook, P.J. 1997. Activation of the lac repressor in the transgenic mouse. Genetics. 147:297-304.
36. Esteller, M., Corn, P.G., Baylin, S.B., and Herman, J.G. 2001. A gene hypermethylation profile of human cancer. Cancer Res, 61:3225-3229.
37. Tycko, B. 2000 Epigenetic gene silencing in cancer. J. Clin. Invest. 105:401-407.
38. Jones, P.A. 2001. Cancer. Death and methylation. Nature. 409:141-144.
39. Song, S.H., et al. 2001. Transcriptional silencing of cyclooxygenase-2 by hyper-methylation of the 5′ CpG island in human gastric carcinoma cells. Cancer Res. 61:4628-4635.
40. Borde-Chiche, P., et al. 2001. Regulation of transcription of the glutathione S-transferase P1 gene by methylation of the minimal promoter in human leukemia cells. Biochem. Pharmacol. 61:605-612.
41. Levine, A., Cantoni, G. L., and Razin, A. 1991. Inhibition of promoter activity by methylation: possible involvement of protein mediators. Proc. Natl. Acad. Sci. USA. 88:6515-6518.
42. Xu, G.L., and Bestor, T.H. 1997. Cytosine methylation targeted to pre-determined sequences. Nat. Genet. 17:376-378.
43. Wassenegger, M. 2000. RNA-directed DNA methylation. Plant Mol. Biol. 43:203-220.
44. Pelissier, T., and Wassenegger, M. 2000. A DNA target of 30 bp is sufficient for RNA-directed DNA methylation. RNA. 6:55-65.
45. Wassenegger, M., Heimes, S., Riedel, L., and Sanger, H.L. 1994. RNA-directed de novo methylation of genomic sequences in plants. Cell. 76:567-576.
46. Wassenegger, M., and Pelissier, T. 1998. A model for RNA-mediated gene silencing in higher plants. Plant Mol. Biol. 37:349-362.
47. Bu, W., et al. 1998. Effects of matrix metalloproteinase inhibitor BB-94 on liver cancer growth and metastasis in a patient-like orthotopic model LCI-D20. Hepatogastroenterology. 45:1056-1061.
48. Scharf, J.G., Dombrowski, F., and Ramadori, G. 2001. The IGF axis and hepatocarcinogenesis. Mol. Pathol. 54:138-144.
49. Lee, O.H., et al. 2000. Identification of angiogenic properties of insulin-like growth factor II in in vitro angiogenesis models. Br. J. Cancer. 82:385-391.
50. Lin, S.B., et al. 1997. Antisense oligodeoxynucleotides of IGF-2 selectively inhibit growth of human hepatoma cells overproducing IGF-2. J. Biochem. (Tokyo). 122:717-722.
51. Henry, S.P., Monteith, D., Bennett, F., and Levin, A.A. 1997. Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-alpha and C-raf kinase. Anticancer Drug Des. 12:409-420.
52. Rudin, C.M., et al. 2001. Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c- raf-1, administered by 24-hour weekly infusion to patients with advanced cancer. Clin. Cancer Res. 7:1214-1220.
53. Karpf, A.R., et al. 1999. Inhibition of DNA methyltransferase stimulates the expression of signal transducer and activator of transcription 1, 2, and 3 genes in colon tumor cells. Proc Natl Acad Sci. USA. 96:14007-14012.
54. Sparwasser, T., Hultner, L., Koch, E.S., Luz, A., Lipford, G.B., and Wagner, H. 1999. Immunostimulatory CpG-oligodeoxynucleotides cause extramedullary murine hemopoiesis. J. Immunol. 162:2368-2374.,
55. Krieg, A.M., et al. 1995. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 374:546-549.
56. Stein, C.A. 1999. Two problems in antisense biotechnology: in vitro delivery and the design of antisense experiments. Biochim. Biophys. Acta. 1489:45-52.